💸 The Tape

At this point, Vireo Growth's acquisition announcements should come with their own recurring calendar invite. But this morning's deal is different in scale and consequence: Vireo is buying its way to the second-largest dispensary network in America — and it's doing it by carving the choicest cuts from a fallen comrade.

The company announced a definitive purchase agreement to acquire cultivation, manufacturing, and retail operations from The Cannabist Company — the distressed MSO formerly known as Columbia Care — across five markets: Colorado, Illinois, Massachusetts, New Jersey, and West Virginia. Total consideration is up to US$35 million: $18.75 million in cash at closing and $16.25 million in seller notes, subject to customary adjustments. Closings will occur in stages through 2026 and into 2027 as regulatory approvals land in each state.

The haul: up to 25 dispensaries, one cultivation asset, and one production facility. Combined with pending deals, Vireo's pro forma footprint reaches approximately 230 dispensaries across 15 states — vaulting it behind only Trulieve in national retail count.

The Acquisition Machine: 2026's Ledger

To appreciate the velocity here, consider what Vireo has announced or closed this year alone:

Schwazze — 45 dispensaries across Colorado and New Mexico. Eaze — California's largest delivery platform. Hawthorne Gardening — the cultivation supply business acquired from Scotts Miracle-Gro. FLUENT — a $30 million debt equitization delivering roughly 74 Florida dispensaries. The Glass House joint venture — 23 California retail locations. C21 Investments — 15 Nevada dispensaries anchored by Silver State Relief. Bridgewell Agribusiness — a $40 million organic food and agricultural supply platform. HA-MD — a 49% stake in two Maryland operations. The Johnstown, New York facility buyback from Innovative Industrial Properties for $88.5 million. The PhytoNatural Pennsylvania retail permit — authorizing six dispensaries in a 450,000-patient market, closed just last Friday. Plus a market-making engagement to support the stock's liquidity as all this equity-fueled dealmaking expands the shareholder base.

That's ten transactions across cannabis retail, cultivation, delivery, real estate, and adjacent agriculture — in roughly seven months. No other cannabis company is operating at anything close to this tempo. CEO John Mazarakis calls it "disciplined and strategic" consolidation toward "one of the most capital efficient, vertically integrated cannabis platforms in the United States." Skeptics call it integration risk stacked on integration risk. Both can be true — and the Cannabist deal will be a major test of which framing wins.

How the Cannabist Assets Fit

What makes this transaction strategically coherent — rather than acquisition for its own sake — is how precisely each market slots into Vireo's existing map.

Colorado is the deepening play. Vireo already commands a significant Colorado presence through Schwazze, and the eight Cannabist dispensaries bolt directly onto that platform. In a mature, hyper-competitive market where density drives purchasing leverage, delivery economics, and brand distribution, going deeper is the only strategy that works. Vireo isn't entering Colorado — it's consolidating it.

Illinois, Massachusetts, New Jersey, and West Virginia are all new state entries — and the selection is telling. Three of the four are limited-license markets with structural protections: New Jersey's adult-use market continues growing with constrained retail licensure, West Virginia is a nascent medical market with minimal competition, and Illinois — fresh off SB 3222's expansion of operational flexibility, drive-through authorization, and the companion medical license pathway for DEA registration — is a $1.5 billion market where retail footholds are exceptionally hard to acquire. Massachusetts is more competitive, and carries the November repeal ballot question as a known risk, but Cannabist's operations there come with established infrastructure at distressed pricing.

Layer this onto the existing map and the geographic logic sharpens further. Vireo now touches the Northeast corridor (New Jersey, Massachusetts, Pennsylvania via PhytoNatural, New York via Johnstown and its legacy operations, Maryland via HA-MD), the Midwest (Minnesota's home base, Illinois), the Mountain West and Southwest (Colorado, New Mexico, Nevada), the Southeast (Florida via FLUENT), and California (Eaze, Glass House JV). Fifteen states. National brand distribution potential. And with Bridgewell and Hawthorne, an agricultural supply layer that serves the broader industry regardless of which cannabis markets outperform.

The Distressed-Asset Math

The price deserves emphasis. Columbia Care was once valued in the billions — one of the original vertically integrated MSOs, a medical cannabis pioneer with institutional research pedigree and a brand portfolio spanning Seed & Strain, Triple Seven, Hedy, gLeaf, and Classix. Its collapse into CCAA proceedings in March, with Chapter 15 recognition in Delaware following in May, is one of the industry's starkest cautionary tales: overexpansion, debt, and execution failures converting a first-mover into a forced seller.

Vireo is paying up to $35 million — with more than 46% of it in seller notes rather than cash — for 25 dispensaries and production assets across five states. Even accounting for the operational work required to stabilize distressed operations, the per-store math is a fraction of replacement cost, let alone what these licenses commanded at the market's peak. The Cannabist's Virginia assets went to Millstreet for $130 million; Vireo is acquiring a five-state package for roughly a quarter of that. This is what buying at the bottom of a consolidation cycle looks like.

The court process adds procedural steps — a sale approval and vesting order from the Ontario court under CCAA, plus state-by-state regulatory sign-offs — and Vireo flagged that additional divestitures could follow as part of portfolio optimization. Not every acquired asset will be a keeper, and management is being upfront about pruning.

The Bottom Line

The cannabis industry spent 2024 and 2025 talking about consolidation. Vireo spent 2026 doing it — and today's deal is the most consequential move yet. Ten transactions, fifteen states, 230 pro forma dispensaries, and the second-largest retail network in the country, assembled largely from distressed sellers, creditor processes, and deferred-equity structures while competitors focused on uplistings and balance sheet repair.

The open question remains execution. Integrating ten acquisitions across cannabis retail, delivery, cultivation supply, and organic agriculture — simultaneously, through staged closings stretching into 2027 — is an operational challenge no cannabis company has ever successfully completed at this scale. Mazarakis is betting that discipline, local execution, and bottom-of-cycle pricing turn this collection into a platform.

If it works, Vireo will have built a national footprint for pennies on the peak-cycle dollar. Columbia Care's assets living on inside the industry's most aggressive consolidator is either poetic or ironic — depending on whether the integration succeeds. Either way, the pace isn't slowing. It never does.

📈 Dog Walkers

Cannabis Calms 87% of Agitated Dementia Patients

The most compelling cannabis research of the year just landed — and it addresses one of medicine's most heartbreaking challenges.

A federally funded, placebo-controlled, double-blind trial found that a combination of THC and CBD produced significant and sustained reductions in agitation among people with Alzheimer's disease and other forms of dementia. The results, presented at the Alzheimer's Association International Conference, are remarkable by any clinical standard: 87% of patients receiving the cannabis medication improved by the end of the 12-week study, compared to just 24% on placebo.

The LiBBY study — funded by the National Institutes of Health and the Alzheimer's Association — enrolled 120 hospice-eligible dementia patients with an average age of 80.5 years, all experiencing clinically significant agitation. The preparation, called T2:C100 and manufactured by MediPharm Labs, contained 2 mg THC and 100 mg CBD. Improvement showed up fast: at just two weeks, 84% of the cannabis group had improved versus 31% on placebo.

Lead investigator Jacobo Mintzer of the Medical University of South Carolina didn't temper his enthusiasm: "Rarely do we see close to 90 percent of patients in a trial respond positively to a new medication." He called the results "a level of response not seen before in clinical trials related to dementia" — offering "grace and peace" to patients in their final stages of life.

The context makes this even more significant. Current agitation treatments — often antipsychotics — carry serious side effects and FDA black-box warnings for elderly dementia patients. The American Medical Association recently acknowledged cannabis "may offer therapeutic benefits for managing agitation in dementia patients, potentially serving as an alternative to antipsychotic medications."

An NIH-funded, gold-standard randomized trial showing near-90% response in end-stage dementia care — arriving weeks after the FDA acknowledged cannabis's accepted medical uses under oath. The evidence base isn't just growing. It's compounding.

Source: Marijuana Moment

📺 Trade To Black

ALJ Julius Locks in August 17th Filing Deadline | TTB Presented by Flowhub

• Organigram Update: The hosts break down Organigram's latest business update — early Sanity Group performance in Germany (~10% market share, in line with expectations) and Canadian category leadership (#1 in flower and vapes) ahead of first consolidated results on August 11.

• Definium's Clinical Position: CMO Dr. Dan Karlin details where Definium stands in its trial program, why its Phase 3 LSD data is considered among the strongest in psychedelics, and the path toward potential FDA approval and commercialization beginning in 2027.

• Big Pharma Validation: Dr. Karlin reacts to Eli Lilly's $2.8 billion acquisition of AtaiBeckley — a landmark deal signaling that major pharmaceutical players are now moving into psychedelic therapeutics rather than watching from the sidelines.

• Rescheduling Timeline: Michael Bronstein explains the post-hearing process — ALJ Derek Julius has set August 17 as the deadline for final briefs, and Bronstein assesses whether a Recommended Decision could realistically arrive before the end of August.